Announcements - OBI Pharma 台灣浩鼎

2020.Jun.22

Announcement of resolution items from 2020 Annual General Meeting

2020.Jun.22

Announcement of 2020 annual general meeting passes removal of the noncompete clause for directors

2020.Jun.10

OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA

2020.May.29

OBI has filed application of Phase I/II human clinical studies for passive immunotherapeutic monoclonal antibody OBI-888 to TFDA

2020.May.26

OBI has signed a non-binding MOU to form a strategic partnership to develop novel bispecific antibody cancer treatments

2020.May.08

Supplementary statement for 2020 Shareholders’ Meeting (Change in location and new items)

2020.Apr.11

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by Ministry of Food and Drug Safety of South Korea to proceed Phase III human clinical study

2020.Apr.08

Due to the tense situation of Novel Coronavirus Disease (COVID-19), company decided to pause the recruitment of Global Phase III clinical study for 3 months and will restart recruitment when epidemic gets controlled.

2020.Mar.25

Updates on company’s negotiable securities for investors’ information

2020.Mar.13

Announcement on change of accountant due to internal adjustment of accounting firm

News

Latest News

Events

Latest events